PreTRM®
Test for Risk Management

Addressing the Catastrophic Impacts of Preterm Birth on Employers

Discover how the PreTRM® Test can bring tangible value to your organization

A HEALTHCARE CRISIS

Preterm birth has significant impact on employers and lasting repercussions on families

- Occurs in 1 in 10 pregnancies in the U.S.[1]
- Is a leading contributor to infant morbidity and mortality[2]
- Costs 10x as much as a full-term birth, driving 61% of total newborn costs[3]
- Leads to short- and long-term health conditions for babies including brain bleeds, respiratory issues, jaundice, vision and hearing loss, learning disabilities, and cerebral palsy[4]
- Affects healthcare outcomes and costs far beyond initial birth

Preterm birth rates in the U.S. vary by ethnic groups, impacting diverse employee populations



By prioritizing access to maternal health offerings, employers can help address racial and ethnic disparities by:

Bringing awareness to this important issue through diversity, equity, and inclusion programs

Providing an innovative solution that helps reduce preterm birth regardless of race/ethnicity

Addressing inequities in care to improve health disparities within diverse populations

PreTRM®

Test for Risk Management

EARLY. INDIVIDUAL. ACCURATE.

The PreTRM® Test enables physicians to more accurately identify and manage preterm birth risk for a better outcome

The PreTRM Test is a simple blood test to predict a woman's individualized risk of spontaneous preterm birth (before 37 weeks) with results provided directly to healthcare providers.

- First and only broadly, clinically validated commercially available test of its kind
- The test measures and analyzes two placentally expressed proteins in the blood that are highly predictive of spontaneous preterm birth in asymptomatic singleton pregnancies.
- A single blood draw during week 18 through 20 of pregnancy with results available from a certified lab in an average of 7 days from the receipt of the sample.
- This test enables more personalized clinical decisions based on each woman's individual risk for preterm birth.

PRETRM REPORT EXAMPLE



Patients identified as higher risk by the PreTRM Test are at increased risk for:[5]

- Spontaneous preterm birth
- Longer neonatal hospital length of stay
- Severe adverse neonatal outcomes

Patients with higher-risk scores generally give birth earlier than lower-risk subjects[6]

IMPROVE OUTCOMES

PreTRM® Test and treat for better maternal and neonatal outcomes

Armed with a patient's individual risk, practitioners are able to intervene with methods that have been shown effective in reducing preterm birth rates and improving outcomes.

Interventions such as proactive care management, progesterone supplementation, low-dose aspirin, cervical length surveillance, cerclage placement, and others, have been shown to achieve:

UP TO

66%

Reduction of severe morbidity and mortality[7-9]

10%

Reduction to Neonatal Intensive Care Unit (NICU) admissions[7]

Reducing the time a baby spends in the NICU after a premature birth

Standard of Care

45.5

average days in NICU[9]

PreTRM® Test

+ Treat Strategy^

6.8

average days in NICU[9]

UP TO

85%

Reduction in time the neonate spent in the NICU following a preterm birth[7-9]

^ Identifying patients at higher risk for spontaneous preterm birth with the PreTRM Test and applying proactive, evidence-based interventions to improve neonatal health and reduce total health costs.

REDUCE COSTS

Health benefits translate into an economic impact

Results projected by a major payer in the Value Advantage Model show the impact of the PreTRM Test and Treat Strategy vs. Standard Care.†^

21%
REDUCTION
in preterm births <37 weeks[7,8]

32%
REDUCTION
in preterm births <35 weeks[7,8]

37%
REDUCTION
in preterm births <32 weeks[7,8]
(very early preemies)

Total Annual Cost Savings[7,8*]

$898,000

$1,022
Savings per pregnant woman tested[7,8*]

$5,611
Savings per pregnant woman shown to be at higher risk[7,8*]

*After PreTRM Test and intervention
†Modeled using ACCORDANT case management treatment size effect and the validated, published payer model.

PreTRM®
Test for Risk Management

Improving maternal and neonatal outcomes demonstrates direct and indirect value to employers

The PreTRM® Test allows employers to benefit from earlier intervention and improved clinical outcomes. Benefits may include:

- Help to reduce stop loss and catastrophic claims
- Close gaps in care and improve health disparities
- Improve employee overall mental, emotional, and physical wellbeing
- Attract and retain talent
- Reduce presenteeism, absenteeism, and resignations

PreTRM® is innovation made easy

Suitable for 88% of pregnant women[10,11]

- Women with a singleton pregnancy
- Asymptomatic for preterm labor

Simple to Administer

- Single blood draw during week 18 through 20, typically coinciding with anatomy scan
- Fast turnaround from our CLIA-certified, CAP-accredited lab in an average of 7 business days from the receipt of sample

How your members will access the PreTRM Test

1. Healthcare provider orders the PreTRM Test – notification sent to Sera
2. Sera Customer Support contacts patient to coordinate blood draw
3. Patient has sample collected in broad network of available collection sites
4. Healthcare provider receives results in an average of 7 business days

Seamlessly integrate PreTRM into your benefits package

No minimum group size • No eligibility file feeds • Flexible pricing options

Ability to work with any health plan/TPA • Can be added to any maternity and/or infertility program

Employer-specific ROI reporting available

To speak with a Market Access Team member, contact **info@seraprognostics.com**

PreTRM®
Test for Risk Management

To speak with a Market Access Team member, contact **info@seraprognostics.com**

References: **1.** Hamilton BE, et al. Births: Provisional data for 2020. Vital Statistics Rapid Release; no 12. Hyattsville, MD: National Center for Health Statistics. May 2021. **2.** Callaghan WM. et al. The contribution of preterm birth to infant mortality rates in the United States. Pediat rics. 2006 Oct;118(4):l566-73. **3.** Waitzman NJ. et al. Preterm birth lifetime costs in the United States in 2016: An update. Semin Perinatol, 2021 Jan 24:151390. doi: 10.1016/j.semperi.2021.151390. **4.** Howson CP, et al. Born Too Soon: Preterm birth matters. Reprod Health 10, Sl (2013). **5.** Burchard J, Polpitiya AD, Fox AC, et al. Clinical validation of a proteomic biomarker threshold for increased risk of spontaneous preterm birth. 2021 https://doi.org/10.1101/2021.01.23.21249902. **6.** Saade GR, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol. 2016;214:633.e1-24. **7.** Grabner M, et al. Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction. Clinicoecon Outcomes Res. 2021. **8.** Burchard, et al. Clinical and economic utility of a preterm birth predictor derived from an analysis of a large and diverse pregnancy cohort. 2021. https://doi.org/10.1101/2021.09.08.21262940. **9.** Branch, et al. Prediction and Prevention of Preterm Birth. Am J Perinatol. 2021. DOI https://doi.org/ 10.1055/s-0041-1732339. **10.** Petrini JR, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol. 2005;105:267-72. **11.** Hassan SS, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38:18-31.

SERA PROGNOSTICS®
The Pregnancy Company®

©2022 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. COLL-138 Rev 2.0 / 05-22